| - |
Corifollitropin alfa |
Elonva® |
Controlled Ovarian Stimulation (COS) in combination with a Gonadotropin Releasing Hormone (GnRH) antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program. |
Rapid Review complete |
22nd October 2010 |
 |
| - |
Crizotinib |
Xalkori® |
Treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) (i.e. in the 2nd / 3rd–line treatment setting) |
NCPE Assessment process complete |
27th August 2013 |
|
| - |
Crizotinib |
Xalkori® |
For the first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). |
Rapid Review complete |
25th April 2017 |
|
| - |
Crizotinib |
Xalkori® |
For the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC). |
Rapid Review complete |
25th April 2017 |
|
| 24027 |
Crovalimab |
Piasky® |
For the treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with paroxysmal nocturnal haemoglobinuria (PNH): (i) In patients with haemolysis with clinical symptom(s) indicative of high disease activity; (ii) In patients who are clinically stable after having been treated with a complement 5 inhibitor for at least the past 6 months |
Rapid Review complete |
2nd August 2024 |
|
| - |
Cysteamine bitartrate delayed-release |
Procysbi® |
For the treatment of proven nephropathic cystinosis. |
NCPE Assessment process complete |
15th November 2017 |
|
| 23063 |
Cytisine |
Citidaron® |
Cytisine (Citidaron®) is indicated for smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking. |
Rapid Review Complete |
5th June 2024 |
|
